| Bioactivity | Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-life. Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway[1][2]. | ||||||||||||
| Name | Fluorofenidone | ||||||||||||
| CAS | 848353-85-5 | ||||||||||||
| Formula | C12H10FNO | ||||||||||||
| Molar Mass | 203.21 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Qin J, et al. Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. Nephrology (Carlton). 2013 Oct;18(10):690-9. [2]. Lou Q, et al. Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones. Molecules. 2012 Jan 17;17(1):884-96. |
Fluorofenidone
CAS: 848353-85-5 F: C12H10FNO W: 203.21
Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-li
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.